中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2013年
8期
831-833
,共3页
冠状动脉搭桥%围手术期%动态血糖监测系统%胰岛素泵
冠狀動脈搭橋%圍手術期%動態血糖鑑測繫統%胰島素泵
관상동맥탑교%위수술기%동태혈당감측계통%이도소빙
Coronary bypass%Perioperative%Glucose monitoring systems%Insulin pump
目的 观察动态血糖监测系统(CGMS)和胰岛素泵皮下输注系统(CSⅡ)组成的双C方案在合并2型糖尿病(T2 DM)的冠状动脉搭桥患者围手术期的临床疗效.方法 将拟行冠状动脉搭桥手术的T2DM患者分为双C治疗组(双C组,n=20)和胰岛素多次皮下注射组(MSⅡ组,n=30),观察两组患者术前、术后血糖的控制值、血糖的波动幅度、胰岛素的用量、血糖达标的时间、低血糖的发生率、切口感染率、总住院时间.结果 双C组和MSⅡ组血糖的波动幅度分别为(5.76±1.42)、(7.91±1.68)mmol/L (P ＜0.05),胰岛素的用量分别为(38.82±16.97)、(49.00±15.32) U/d(P =0.032),血糖的达标时间分别为(3.52±1.13)、(6.00±4.27) d(P =0.002),发生低血糖分别为4例和1例(P =0.025),切口感染均为1例(P =0.948),总住院时间分别为(23.68±13.67)、(30.12±2.94) d(P =0.084).结论 采用双C方案对冠状动脉搭桥患者围术期的血糖控制更加全面和有效.
目的 觀察動態血糖鑑測繫統(CGMS)和胰島素泵皮下輸註繫統(CSⅡ)組成的雙C方案在閤併2型糖尿病(T2 DM)的冠狀動脈搭橋患者圍手術期的臨床療效.方法 將擬行冠狀動脈搭橋手術的T2DM患者分為雙C治療組(雙C組,n=20)和胰島素多次皮下註射組(MSⅡ組,n=30),觀察兩組患者術前、術後血糖的控製值、血糖的波動幅度、胰島素的用量、血糖達標的時間、低血糖的髮生率、切口感染率、總住院時間.結果 雙C組和MSⅡ組血糖的波動幅度分彆為(5.76±1.42)、(7.91±1.68)mmol/L (P ＜0.05),胰島素的用量分彆為(38.82±16.97)、(49.00±15.32) U/d(P =0.032),血糖的達標時間分彆為(3.52±1.13)、(6.00±4.27) d(P =0.002),髮生低血糖分彆為4例和1例(P =0.025),切口感染均為1例(P =0.948),總住院時間分彆為(23.68±13.67)、(30.12±2.94) d(P =0.084).結論 採用雙C方案對冠狀動脈搭橋患者圍術期的血糖控製更加全麵和有效.
목적 관찰동태혈당감측계통(CGMS)화이도소빙피하수주계통(CSⅡ)조성적쌍C방안재합병2형당뇨병(T2 DM)적관상동맥탑교환자위수술기적림상료효.방법 장의행관상동맥탑교수술적T2DM환자분위쌍C치료조(쌍C조,n=20)화이도소다차피하주사조(MSⅡ조,n=30),관찰량조환자술전、술후혈당적공제치、혈당적파동폭도、이도소적용량、혈당체표적시간、저혈당적발생솔、절구감염솔、총주원시간.결과 쌍C조화MSⅡ조혈당적파동폭도분별위(5.76±1.42)、(7.91±1.68)mmol/L (P ＜0.05),이도소적용량분별위(38.82±16.97)、(49.00±15.32) U/d(P =0.032),혈당적체표시간분별위(3.52±1.13)、(6.00±4.27) d(P =0.002),발생저혈당분별위4례화1례(P =0.025),절구감염균위1례(P =0.948),총주원시간분별위(23.68±13.67)、(30.12±2.94) d(P =0.084).결론 채용쌍C방안대관상동맥탑교환자위술기적혈당공제경가전면화유효.
Objective To observe the clinical efficacy of the double C program consisting of glucose monitoring systems (CGMS) and insulin pump (CSⅡ) in perioperative period of patients undergoing coronary artery bypass patients with type2 diabetes mellitus (T2DM).Methods Divided participants who underwent coronary artery bypass surgery with T2DM into double C treatment group (double C group,n =20) and multiple subcutaneous insulin group (MSⅡ group,n =30).Before and after surgery,blood sugar control in blood glucose time,blood sugar fluctuations,the amount of insulin,the incidence of low blood sugar,incision infection,and total hospitalization days were observed.Results Comparing the double C treatment group with the MSⅡ group,blood sugar fluctuations ((5.76 ± 1.42) mmol/L vs.(7.91 ± 1.68) mmol/L,P ＜ 0.05),the amount of insulin ((38.82 ± 16.97) U/d vs.(49.00 ± 15.32) U/d,P =0.032),the blood sugar compliance time ((3.52 ± 1.13) d vs.(6.00 ± 4.27) d,P =0.002),hypoglycemia (4 cases vs.1 case,P =0.025),the incision infection rates in both the cases(P =0.948),the total admission days((23.68 ± 13.67) d vs.(30.12 ± 2.94) d,P =0.084).Conclusion The double C program is comprehensively effective.for the perioperative glycemic control of patients with T2DM undergoing coronary artery bypass.
